Currently, Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs) are used in several CVD scenarios, such as in patients with hypertension, for secondary prevention after myocardial infarction, as well as for the management of heart failure with reduced ejection fraction (HFrEF), and their cardiovascular benefit has already been well-established [108,109]. Here, ACE is linked to myocardial infarction.